Paritosh Garg/LinkedIn
Apr 12, 2026, 14:15
Paritosh Garg: A fibrotic marrow is not always PMF
Paritosh Garg, Associate Consultant at Fortis Memorial Research Institute, India, shared a post on LinkedIn:
“A fibrotic marrow is not always PMF.
One recent case reminded me of this very clearly.
A young woman presented with severe cytopenias, a leucoerythroblastic smear, and grade 2 marrow fibrosis.
The initial marrow appearance was concerning — but the rest of the story mattered.
There was:
- no splenomegaly
- no atypical megakaryocytes
- no significant dysplasia
- no convincing clonal marker
- autoimmune features supporting an immune-mediated process
Her treatment journey was equally telling:
- relapsed on steroids
- did not respond to MMF / cyclosporine / danazol
- finally responded to rituximab
For me, the takeaway was powerful:
- when fibrosis is seen in the marrow, especially in a young patient with autoimmune clues, autoimmune myelofibrosis must remain on the radar.
In hematology, morphology opens the door.
But diagnosis still belongs to the whole clinical picture.”
Stay updated with Hemostasis Today.
-
Apr 12, 2026, 14:18Jean Jacques Kiladjian: Grateful to the MSH for the invitation to ‘Highlights of ASH’ in Asia-Pacific 2026
-
Apr 12, 2026, 14:13Scott Woller: ACC/AHA Guidelines and the Role of Pulmonary Embolism Response Teams
-
Apr 12, 2026, 13:55Ifeanyichukwu Ifechidere: When Fibrinogen isn’t Really Fibrinogen
-
Apr 12, 2026, 13:53Alan Nurden: A Contemporary Update on the Pathogenesis of Inherited Platelet Dysfunction
-
Apr 12, 2026, 13:47Kalyan Roy: Visual Inspection of Blood Bags and Blood Products
-
Apr 12, 2026, 13:44Francisco Ujueta: PAD VS CAD – Why Individualized Antithrombotic Strategies Matter
-
Apr 12, 2026, 13:42William Aird: Anemia of Inflammation Not Just a Trade-Off but a Possible Compensation
-
Apr 12, 2026, 13:38Emmanuel J Favaloro: D-dimer testing in VTE diagnostic management studies
-
Apr 12, 2026, 13:26Flora Peyvandi: What Can Be Alternative to Warfarin